Form D
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
GENESIS BIOPHARMA, INC
Jurisdiction of Incorporation/Organization
NE
Year of Incorporation/Organization
Over Five Years Ago
Item 2 Issuer Principal Place of Business and Contact Information
10960 WILSHIRE BOULEVARD
SUITE 1050
LOS ANGELES, CA 90024
Phone Number:
subscription required
Item 3. Related Persons
Name
MICHAEL HANDELMAN
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
PAUL KESSLER
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
DAVID VOYTICKY
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
MERRILL MCPEAK
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 4. Industry Group
BIOTECHNOLOGY
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
DECLINE TO DISCLOSE
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
New Notice
Date of First Sale in this Offering:
05/22/2013
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
No
Item 9. Type(s) of Securities Offered
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
0
Item 13. Offering and Sales Amounts
Total Offering Amount
1350000
Total Amount Sold
1350000
Total Remaining to be Sold
0
Clarification of Response
$1,350,000 IN CASH, OTHER CONSIDERATION IN THE CANCELLATION OF $9,267,640 IN DEBT AND THE EXCHANGE OF 12,273,418 WARRANTS.
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
30
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
0.0
Clarification of Response
NONE, OTHER THAN COMPENSATION TO EXECUTIVE OFFICERS IN THEIR ROLES AS EMPLOYEES.
Signature and Submission
Issuer Name
GENESIS BIOPHARMA, INC
Issuer Signature
/S/ MICHAEL HANDELMAN
Signer Name
MICHAEL HANDELMAN
Signer Title
CHIEF FINANCIAL OFFICER
Signature Date
06/06/2013
